Evidence map›Paper›PMID 34188197›Full record

ArticleBritish journal of cancer2021

The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon.

Kun-Han Lee, Wei-Shone Chen, Jeng-Kai Jiang, Shung-Haur Yang, Huann-Sheng Wang, Shih-Ching Chang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Sheng-Chieh Huang and 3 more

Open access · hybridAbstract readClinical StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Kun-Han LeeDepartment of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID http://orcid.org/0000-0002-0951-8610
Wei-Shone ChenSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Jeng-Kai JiangSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Shung-Haur YangSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Huann-Sheng WangSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Shih-Ching ChangSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Yuan-Tzu LanSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Chun-Chi LinSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Hung-Hsin LinSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Sheng-Chieh HuangSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Hou-Hsuan ChengSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Yee ChaoSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Hao-Wei TengSchool of Medicine, National Yang-Ming University, Taipei, Taiwan. hwteng1971@gmail.com.ORCID http://orcid.org/0000-0001-8480-3422
National Yang Ming Chiao Tung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinically, metastatic rectal cancer has been considered a subset of left-sided colon cancer. However, heterogeneity has been proposed to exist between high and middle/low rectal cancers. We aimed to examine the efficacy of anti-epidermal growth factor receptor (EGFR) treatment for middle/low rectal and left-sided colon cancers.

methodsThis study enrolled 609 patients with metastatic colorectal cancer who were treated with anti-EGFR therapy. They were divided into groups based on primary tumour locations: the right-sided colon, the left-sided colon or the middle/low rectum. The efficacy of first-line and non-first-line anti-EGFR treatment was analysed. Genomic differences in colorectal cancer data from The Cancer Genome Atlas (TCGA) were investigated and visualised with OncoPrint and a clustered heatmap.

resultsOn first-line anti-EGFR treatment, patients with middle/low rectal tumours had significantly lower progression-free survival, overall survival, and overall response rates (6.8 months, 27.8 months and 43%, respectively) than those with left-sided colon cancer (10.1 months, 38.3 months and 66%, respectively). Similar outcomes were also identified on non-first-line anti-EGFR treatment. In TCGA analysis, rectal tumours displayed genetic heterogeneity and shared features with both left- and right-sided colon cancer.

conclusionsAnti-EGFR treatment has lower efficacy in metastatic middle/low rectal cancer than in left-sided colon cancer.

Indexed as

CetuximabColonColorectal NeoplasmsDatabases, GeneticEpigenomicsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleNeoplasm MetastasisPanitumumabRectumRetrospective StudiesSurvival AnalysisTreatment OutcomeCetuximabPanitumumab

Identifiers

PMID34188197
PMCPMC8437976
OpenAlexW3177041210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.